share_log

BARDA Backs Arcturus' Influenza Vaccine Program

Benzinga Real-time News ·  Sep 1, 2022 10:06
  • Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) received an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA).
  • The award provides three years to support preclinical, manufacturing, and nonclinical safety studies, along with development and regulatory support for Arcturus' self-amplifying mRNA vaccine platform technology for rapid pandemic influenza response through Phase 1 studies.
  • Also see: Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants.
  • The company says its self-amplifying mRNA vaccine has been administered to over 10,000 individuals globally, demonstrating favorable safety, strong immunogenicity, and protection against SARS-COV-2 infection.
  • Price Action: ARCT shares are down 2.68% at $13.66 on the last check Thursday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment